You are here
Guidelines on the evidence required to support indications for listed complementary medicines
|Version||Description of change||Author||Effective date|
|V1.0||Original publication||Therapeutic Goods Administration, Office of Complementary Medicines||October 2001|
|V1.1||Change of format||Therapeutic Goods Administration, Office of Complementary Medicines||April 2011|
|V2.0||Revision||Therapeutic Goods Administration, Office of Complementary Medicines||March 2014|
|V2.1||Row 1,Table 6, page 41 correction of BMI range to state 25-30kg/m2||Therapeutic Goods Administration, Office of Complementary Medicines||July 2014|
Reviewed to incorporate amendments to the Act that came into effect March 2018 that introduced permitted indications for listed medicines and the assessed listed pathway.
Updated indication examples and updated information on biomarker indications to be consistent with permitted indications for listed medicines.
Removal of duplicate information available in other guidance material on the TGA website (e.g. ARGCM, ARGATC).
Formatting changes, correction of: links; typographical; and grammatical errors.
|Therapeutic Goods Administration, Office of Complementary & Over the Counter Medicines||February 2019|